Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7929531rdf:typepubmed:Citationlld:pubmed
pubmed-article:7929531lifeskim:mentionsumls-concept:C0030551lld:lifeskim
pubmed-article:7929531lifeskim:mentionsumls-concept:C1513095lld:lifeskim
pubmed-article:7929531lifeskim:mentionsumls-concept:C0028458lld:lifeskim
pubmed-article:7929531lifeskim:mentionsumls-concept:C0004565lld:lifeskim
pubmed-article:7929531lifeskim:mentionsumls-concept:C1861502lld:lifeskim
pubmed-article:7929531pubmed:issue10lld:pubmed
pubmed-article:7929531pubmed:dateCreated1994-10-28lld:pubmed
pubmed-article:7929531pubmed:abstractTextThe effect of the antibiotic agent novobiocin on the sensitivity of melanoma cells to colchicine and vinblastine was examined in drug-sensitive and drug-resistant B16 melanoma cells. A cell line COL/R was selected for colchicine resistance. The COL/R cell line (resistant to 80 ng/ml colchicine) was found to possess the multidrug-resistant (MDR) phenotype. The cells were shown to be cross-resistant to vinblastine and Adriamycin and to overexpress P glycoprotein. P glycoprotein activity was assessed by using the rhodamine 123 accumulation test. Rhodamine accumulation was markedly decreased in COL/R cells as compared to the parental B16 cells. Verapamil reversed drug resistance and increased rhodamine accumulation in COL/R cells. Novobiocin in combination with colchicine or vinblastine synergistically inhibited the proliferation of parental B16 cells. In COL/R cells, novobiocin markedly decreased colchicine resistance and increased rhodamine accumulation. These data show that novobiocin increases the sensitivity of both parental and MDR melanoma cells to microtubule-disrupting cytotoxic drugs.lld:pubmed
pubmed-article:7929531pubmed:languageenglld:pubmed
pubmed-article:7929531pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7929531pubmed:citationSubsetIMlld:pubmed
pubmed-article:7929531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7929531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7929531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7929531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7929531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7929531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7929531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7929531pubmed:statusMEDLINElld:pubmed
pubmed-article:7929531pubmed:issn0171-5216lld:pubmed
pubmed-article:7929531pubmed:authorpubmed-author:NovogrodskyAAlld:pubmed
pubmed-article:7929531pubmed:authorpubmed-author:SidiYYlld:pubmed
pubmed-article:7929531pubmed:authorpubmed-author:NordenbergJJlld:pubmed
pubmed-article:7929531pubmed:authorpubmed-author:HalabeEElld:pubmed
pubmed-article:7929531pubmed:authorpubmed-author:WassermanLLlld:pubmed
pubmed-article:7929531pubmed:authorpubmed-author:LandauOOlld:pubmed
pubmed-article:7929531pubmed:authorpubmed-author:BeeryEElld:pubmed
pubmed-article:7929531pubmed:authorpubmed-author:KornfeldJJlld:pubmed
pubmed-article:7929531pubmed:authorpubmed-author:ShafranMMlld:pubmed
pubmed-article:7929531pubmed:issnTypePrintlld:pubmed
pubmed-article:7929531pubmed:volume120lld:pubmed
pubmed-article:7929531pubmed:ownerNLMlld:pubmed
pubmed-article:7929531pubmed:authorsCompleteYlld:pubmed
pubmed-article:7929531pubmed:pagination599-604lld:pubmed
pubmed-article:7929531pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:meshHeadingpubmed-meshheading:7929531-...lld:pubmed
pubmed-article:7929531pubmed:year1994lld:pubmed
pubmed-article:7929531pubmed:articleTitleNovobiocin modulates colchicine sensitivity in parental and multidrug-resistant B16 melanoma cells.lld:pubmed
pubmed-article:7929531pubmed:affiliationEndocrinology Laboratory, Beilinson Medical Center, Petah Tiqva, Israel.lld:pubmed
pubmed-article:7929531pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7929531pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:7929531pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7929531lld:pubmed